antidepressive agents

Summary

Summary: Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.

Top Publications

  1. ncbi Selective publication of antidepressant trials and its influence on apparent efficacy
    Erick H Turner
    Department of Psychiatry, Oregon Health and Science University, Portland, OR, USA
    N Engl J Med 358:252-60. 2008
  2. ncbi Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
    Andrea Cipriani
    Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Italy Department of Psychiatry, University of Oxford, UK
    Lancet 373:746-58. 2009
  3. ncbi Depression: a new animal model sensitive to antidepressant treatments
    R D Porsolt
    Nature 266:730-2. 1977
  4. ncbi A neurotrophic model for stress-related mood disorders
    Ronald S Duman
    Division of Molecular Psychiatry, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06508, USA
    Biol Psychiatry 59:1116-27. 2006
  5. pmc mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists
    Nanxin Li
    Laboratory of Molecular Psychiatry, Center for Genes and Behavior, Department of Psychiatry, Yale University School of Medicine, 34 Park Street, New Haven, CT 06508, USA
    Science 329:959-64. 2010
  6. ncbi Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
    Luca Santarelli
    Center for Neurobiology and Behavior, Columbia University, New York, NY 10032, USA
    Science 301:805-9. 2003
  7. pmc Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration
    Irving Kirsch
    Department of Psychology, University of Hull, Hull, United Kingdom
    PLoS Med 5:e45. 2008
  8. ncbi Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9086, USA
    Am J Psychiatry 163:1905-17. 2006
  9. ncbi A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
    Carlos A Zarate
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, MD 20892, USA
    Arch Gen Psychiatry 63:856-64. 2006
  10. ncbi The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity
    Eero Castren
    Sigrid Jusélius Laboratory, Neuroscience Center, University of Helsinki, Helsinki, Finland
    Dev Neurobiol 70:289-97. 2010

Detail Information

Publications279 found, 100 shown here

  1. ncbi Selective publication of antidepressant trials and its influence on apparent efficacy
    Erick H Turner
    Department of Psychiatry, Oregon Health and Science University, Portland, OR, USA
    N Engl J Med 358:252-60. 2008
    ..Selective publication of clinical trials--and the outcomes within those trials--can lead to unrealistic estimates of drug effectiveness and alter the apparent risk-benefit ratio...
  2. ncbi Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
    Andrea Cipriani
    Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Italy Department of Psychiatry, University of Oxford, UK
    Lancet 373:746-58. 2009
    ..We therefore did a multiple-treatments meta-analysis, which accounts for both direct and indirect comparisons, to assess the effects of 12 new-generation antidepressants on major depression...
  3. ncbi Depression: a new animal model sensitive to antidepressant treatments
    R D Porsolt
    Nature 266:730-2. 1977
  4. ncbi A neurotrophic model for stress-related mood disorders
    Ronald S Duman
    Division of Molecular Psychiatry, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06508, USA
    Biol Psychiatry 59:1116-27. 2006
    ....
  5. pmc mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists
    Nanxin Li
    Laboratory of Molecular Psychiatry, Center for Genes and Behavior, Department of Psychiatry, Yale University School of Medicine, 34 Park Street, New Haven, CT 06508, USA
    Science 329:959-64. 2010
    ..Our results demonstrate that these effects of ketamine are opposite to the synaptic deficits that result from exposure to stress and could contribute to the fast antidepressant actions of ketamine...
  6. ncbi Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
    Luca Santarelli
    Center for Neurobiology and Behavior, Columbia University, New York, NY 10032, USA
    Science 301:805-9. 2003
    ..These findings suggest that the behavioral effects of chronic antidepressants may be mediated by the stimulation of neurogenesis in the hippocampus...
  7. pmc Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration
    Irving Kirsch
    Department of Psychology, University of Hull, Hull, United Kingdom
    PLoS Med 5:e45. 2008
    ..The purpose of this analysis is to establish the relation of baseline severity and antidepressant efficacy using a relevant dataset of published and unpublished clinical trials...
  8. ncbi Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9086, USA
    Am J Psychiatry 163:1905-17. 2006
    ..This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial...
  9. ncbi A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
    Carlos A Zarate
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, MD 20892, USA
    Arch Gen Psychiatry 63:856-64. 2006
    ..Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders...
  10. ncbi The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity
    Eero Castren
    Sigrid Jusélius Laboratory, Neuroscience Center, University of Helsinki, Helsinki, Finland
    Dev Neurobiol 70:289-97. 2010
    ....
  11. ncbi Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
    Olivier Berton
    Department of Psychiatry and Center for Basic Neuroscience, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9070, USA
    Science 311:864-8. 2006
    ..These results establish an essential role for BDNF in mediating long-term neural and behavioral plasticity in response to aversive social experiences...
  12. doi Major depressive disorder
    R H Belmaker
    Ben Gurion University of the Negev, Beersheba, Israel
    N Engl J Med 358:55-68. 2008
  13. ncbi The tail suspension test: a new method for screening antidepressants in mice
    L Steru
    Psychopharmacology (Berl) 85:367-70. 1985
    ....
  14. ncbi Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
    Nadia M Tsankova
    The University of Texas Southwestern Medical Center, Department of Psychiatry and Center for Basic Neuroscience, 5323 Harry Hines Boulevard, Dallas, Texas 75390 9070, USA
    Nat Neurosci 9:519-25. 2006
    ..These experiments underscore an important role for histone remodeling in the pathophysiology and treatment of depression and highlight the therapeutic potential for histone methylation and deacetylation inhibitors in depression...
  15. pmc Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications
    Srijan Sen
    Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, Connecticut 06519, USA
    Biol Psychiatry 64:527-32. 2008
    ..Converging lines of evidence implicate the neurotrophin brain-derived neurotrophic factor (BDNF) in the pathophysiology of major depression. Recent studies have begun to explore the relationship between serum BDNF and depression...
  16. ncbi Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment
    Elisabeth B Binder
    Max Planck Institute of Psychiatry, Kraepelinstr 2 10, 80804 Munich, Germany
    Nat Genet 36:1319-25. 2004
    ..These findings support a central role of genes regulating the HPA axis in the causality of depression and the mechanism of action of antidepressant drugs...
  17. pmc Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database
    Michael Moore
    University of Southampton, Aldermoor Health Centre, Southampton SO16 5ST
    BMJ 339:b3999. 2009
    ..Review methods Detailed analysis of general practitioner consultations and antidepressant prescribing was restricted to 170 practices that were contributing data for the full duration of the study...
  18. pmc Antidepressant drug effects and depression severity: a patient-level meta-analysis
    Jay C Fournier
    Department of Psychology, University of Pennsylvania, 3720 Walnut St, Philadelphia, PA 19104, USA
    JAMA 303:47-53. 2010
    ....
  19. pmc Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials
    Dirk Eyding
    German Cancer Society, Berlin, Germany
    BMJ 341:c4737. 2010
    ..To assess the benefits and harms of reboxetine versus placebo or selective serotonin reuptake inhibitors (SSRIs) in the acute treatment of depression, and to measure the impact of potential publication bias in trials of reboxetine...
  20. ncbi Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial
    Jurgen Unutzer
    Center for Health Services Research, UCLA Neuropsychiatric Institute, 10920 Wilshire Blvd, Suite 300, Los Angeles, CA 90024, USA
    JAMA 288:2836-45. 2002
    ..Few depressed older adults receive effective treatment in primary care settings...
  21. ncbi Placebo response in studies of major depression: variable, substantial, and growing
    B Timothy Walsh
    Department of Psychiatry, College of Physicians and Surgeons of Columbia University, 1051 Riverside Dr, Unit 98, New York, NY 10032, USA
    JAMA 287:1840-7. 2002
    ..There is continuing interest in the development of new medications, but because effective antidepressants are already available, ethical concerns have been raised about the need for placebo groups in new trials...
  22. ncbi New approaches to antidepressant drug discovery: beyond monoamines
    Olivier Berton
    Department of Psychiatry and Center for Basic Neuroscience, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390 9070, USA
    Nat Rev Neurosci 7:137-51. 2006
    ..This review summarizes the obstacles that have hindered the development of non-monoamine-based antidepressants, and provides a progress report on some of the most promising current strategies...
  23. ncbi The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice
    John F Cryan
    Psychiatry Program, Neuroscience Research, The Novartis Institutes for BioMedical Research WSJ 386 344, Novartis Pharma AG, CH 4002 Basel, Switzerland
    Neurosci Biobehav Rev 29:571-625. 2005
    ..Taken together, we conclude that the tail suspension test is a useful test for assessing the behavioural effects of antidepressant compounds and other pharmacological and genetic manipulations relevant to depression...
  24. pmc Antidepressants increase neural progenitor cells in the human hippocampus
    Maura Boldrini
    Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, 1051 Riverside Drive, Box 42, New York, NY 10032, USA
    Neuropsychopharmacology 34:2376-89. 2009
    ..009). Antidepressants increase NPC number in the anterior human DG. Whether this finding is critical or necessary for the antidepressants effect remains to be determined...
  25. pmc Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders
    Gerard Sanacora
    Department of Psychiatry, Clinical Neuroscience Research Unit, Yale University School of Medicine, New Haven, CT, USA
    Neuropharmacology 62:63-77. 2012
    ..This article is part of a Special Issue entitled 'Anxiety and Depression'...
  26. ncbi Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study
    Y I Sheline
    Department of Psychiatry, Washington University, St. Louis, Missouri 63110, USA
    Biol Psychiatry 50:651-8. 2001
    ..CONCLUSIONS: Depressed patients have left amygdala hyperarousal, even when processing stimuli outside conscious awareness. Increased amygdala activation normalizes with antidepressant treatment...
  27. ncbi Depression screening and patient outcomes in cardiovascular care: a systematic review
    Brett D Thombs
    Department of Psychiatry, McGill University, Montreal, Quebec, Canada
    JAMA 300:2161-71. 2008
    ..Several practice guidelines recommend that depression be evaluated and treated in patients with cardiovascular disease, but the potential benefits of this are unclear...
  28. pmc Signaling pathways underlying the rapid antidepressant actions of ketamine
    Ronald S Duman
    Departments of Psychiatry and Neurobiology, Yale University School of Medicine, 34 Park Street, New Haven, CT 06508, USA
    Neuropharmacology 62:35-41. 2012
    ..These findings identify new targets for rapid acting antidepressants that are safer than ketamine. This article is part of a Special Issue entitled 'Anxiety and Depression'...
  29. ncbi New insights into BDNF function in depression and anxiety
    Keri Martinowich
    Mood and Anxiety Program, National Institute of Mental Health, Building 35, Room 1C1004, 35 Convent Drive, MSC 3714, Bethesda, Maryland 20892 3714, USA
    Nat Neurosci 10:1089-93. 2007
    ..Opposing influences of mBDNF and proBDNF on long-term potentiation and long-term depression might contribute to the dichotomy of BDNF actions on behaviors mediated by the brain stress and reward systems...
  30. ncbi Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data
    M Reis
    Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linkoping, Sweden
    Psychol Med 40:1723-33. 2010
    ..Concerns have been expressed about possible adverse effects of the use of antidepressant medication during pregnancy, including risk for neonatal pathology and the presence of congenital malformations...
  31. pmc Fluoxetine targets early progenitor cells in the adult brain
    Juan M Encinas
    Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
    Proc Natl Acad Sci U S A 103:8233-8. 2006
    ..This finding defines a cellular target for antidepressant drug therapies...
  32. ncbi Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial
    Lisa F Berkman
    Harvard University, Boston, MA, USA
    JAMA 289:3106-16. 2003
    ..Depression and low perceived social support (LPSS) after myocardial infarction (MI) are associated with higher morbidity and mortality, but little is known about whether this excess risk can be reduced through treatment...
  33. ncbi Increasing use of antidepressants in pregnancy
    William O Cooper
    Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232 2504, USA
    Am J Obstet Gynecol 196:544.e1-5. 2007
    ..The purpose of this study was to quantify the rate of exposures to antidepressants during pregnancy in a large cohort of women...
  34. ncbi Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal
    Alexandre Surget
    U930, INSERM, Universite Francois Rabelais de Tours, Tours, France
    Biol Psychiatry 64:293-301. 2008
    ..We investigated causality between changes in hippocampal neurogenesis and the effects of both chronic stress and chronic ADs...
  35. ncbi Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression
    Hiroyuki Koike
    Discovery Pharmacology, Molecular Function and Pharmacology Laboratories, Taisho Pharmaceutical Co, Ltd, 1 403 Yoshino cho, Kita ku, Saitama, Saitama 331 9530, Japan
    Behav Brain Res 224:107-11. 2011
    ....
  36. ncbi Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment
    C M Pariante
    Section of Clinical Neuropharmacology, Institute of Psychiatry, King's College London, London, United Kingdom
    Biol Psychiatry 49:391-404. 2001
    ..Further elucidation of the biochemical and molecular mechanisms involved in GR changes in major depression is an exciting frontier that will no doubt lead to new insights into the pathophysiology and treatment of affective disorders...
  37. ncbi Association of cerebrovascular events with antidepressant use: a case-crossover study
    Chi Shin Wu
    Department of Psychiatry, Far Eastern Memorial Hospital, Taipei, Taiwan
    Am J Psychiatry 168:511-21. 2011
    ..The authors sought to assess the risk of cerebrovascular events associated with use of antidepressant medications...
  38. ncbi Frequency of depression after stroke: a systematic review of observational studies
    Maree L Hackett
    George Institute for International Health, Neurological Diseases and Ageing Division, Royal Prince Alfred Hospital and the University of Sydney, Australia
    Stroke 36:1330-40. 2005
    ..Although depression is an important sequelae of stroke, there is uncertainty regarding its frequency and outcome...
  39. ncbi Cytokines and major depression
    Olga J G Schiepers
    Department of Psychiatry and Neuropsychology, Maastricht University, P O Box 616, 6200 MD Maastricht, The Netherlands
    Prog Neuropsychopharmacol Biol Psychiatry 29:201-17. 2005
    ....
  40. ncbi Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication
    B Chen
    Department of Psychiatry and Behavioral Neuroscience, McMaster University, Hamilton, Ontario, Canada
    Biol Psychiatry 50:260-5. 2001
    ..CONCLUSIONS: These findings are consistent with recent studies measuring CREB levels in this same subject sample, and support current animal and cellular models of antidepressant function...
  41. ncbi Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis
    A C Ford
    Gastroenterology Division, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, L8N 3Z5, Canada
    Gut 58:367-78. 2009
    ..Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder. Evidence for treatment of the condition with antidepressants and psychological therapies is conflicting...
  42. ncbi Antidepressants and body weight: a comprehensive review and meta-analysis
    Alessandro Serretti
    Institute of Psychiatry, University of Bologna, Viale Carlo Pepoli 5, 40123 Bologna, Italy
    J Clin Psychiatry 71:1259-72. 2010
    ..There is evidence that antidepressant drugs may induce a variable amount of weight gain, but results are sparse and often contradictory...
  43. pmc Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor
    C Anacker
    King s College London, Institute of Psychiatry, Section of Perinatal Psychiatry and Stress, Psychiatry and Immunology SPI Lab, Department of Psychological Medicine, London, UK
    Mol Psychiatry 16:738-50. 2011
    ..Our data point toward an important role for the GR in the antidepressant-induced modulation of neurogenesis in humans...
  44. ncbi Antidepressant effect on connectivity of the mood-regulating circuit: an FMRI study
    Amit Anand
    Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Neuropsychopharmacology 30:1334-44. 2005
    ....
  45. pmc Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration
    Marc Stone
    Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993 0002, USA
    BMJ 339:b2880. 2009
    ..To examine the risk of suicidal behaviour within clinical trials of antidepressants in adults...
  46. pmc Cholinergic interneurons in the nucleus accumbens regulate depression-like behavior
    Jennifer L Warner-Schmidt
    Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 109:11360-5. 2012
    ....
  47. ncbi Diagnosis and definition of treatment-resistant depression
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 53:649-59. 2003
    ..It is apparent that there may be varying degrees of treatment resistance. Some staging methods to assess levels of treatment resistance in depression are being developed, but need to be tested empirically...
  48. ncbi The role of glutamate on the action of antidepressants
    Kenji Hashimoto
    Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan
    Prog Neuropsychopharmacol Biol Psychiatry 35:1558-68. 2011
    ..In this article, the author reviews the role of glutamate in the neuron-glia communication induced by potential antidepressants...
  49. ncbi A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression
    Marcus Ising
    Max Planck Institute of Psychiatry, Munich 80804, Germany
    Arch Gen Psychiatry 66:966-75. 2009
    ..Genetic factors and clinical characteristics contribute to the failure of a favorable treatment outcome...
  50. ncbi Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment
    Dominique L Musselman
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Biol Psychiatry 54:317-29. 2003
    ..Future research will confirm whether response to psychotherapy and/or psychopharmacologic treatment improves glucose control, encourages compliance with diabetes treatment, and perhaps even increases longevity...
  51. ncbi The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder
    Piotr Gałecki
    Department of Adult Psychiatry, Medical University of Łódź, Poland
    J Affect Disord 138:360-6. 2012
    ....
  52. pmc Antidepressant use and risk of adverse outcomes in older people: population based cohort study
    Carol Coupland
    Division of Primary Care, University of Nottingham, Nottingham NG7 2RD, UK
    BMJ 343:d4551. 2011
    ..To investigate the association between antidepressant treatment and risk of several potential adverse outcomes in older people with depression and to examine risks by class of antidepressant, duration of use, and dose...
  53. ncbi Genome-wide pharmacogenetics of antidepressant response in the GENDEP project
    Rudolf Uher
    Medical Research Council Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, King s College London, SE5 8AF, London, United Kingdom
    Am J Psychiatry 167:555-64. 2010
    ..The authors performed a genome-wide association analysis of improvement of depression severity with two antidepressant drugs...
  54. ncbi The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine
    N Muller
    Hospital for Psychiatry and Psychotherapy, Ludwig Maximilians Universitat, Munchen, Germany
    Mol Psychiatry 11:680-4. 2006
    ..Moreover, the fact that treatment with an anti-inflammatory drug showed beneficial effects on MD indicates that inflammation is related to the pathomechanism of the disorder, although the exact mechanisms remain to become elucidated...
  55. ncbi Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
    Christian de Bodinat
    Institut de Recherches Internationales Servier, 6 place des Pleiades, 92415 Courbevoie, Cedex, France
    Nat Rev Drug Discov 9:628-42. 2010
    ....
  56. pmc Biomarkers predicting treatment outcome in depression: what is clinically significant?
    Rudolf Uher
    Institute of Psychiatry, King s College London, 16 De Crespigny Park, SE5 8AF, London, UK
    Pharmacogenomics 13:233-40. 2012
    ..To extend to biomarker studies the consensus clinical significance criterion of a three-point difference in Hamilton Rating Scale for Depression...
  57. pmc Impact of reporting bias in network meta-analysis of antidepressant placebo-controlled trials
    Ludovic Trinquart
    French Cochrane Centre, Paris, France
    PLoS ONE 7:e35219. 2012
    ..Indirect comparisons of competing treatments by network meta-analysis (NMA) are increasingly in use. Reporting bias has received little attention in this context. We aimed to assess the impact of such bias in NMAs...
  58. ncbi Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn
    Christina D Chambers
    Department of Pediatrics, University of California, San Diego, La Jolla, CA 92103, USA
    N Engl J Med 354:579-87. 2006
    ..We performed a case-control study to assess whether PPHN is associated with exposure to SSRIs during late pregnancy...
  59. ncbi Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events
    K Demyttenaere
    Department of Psychiatry, University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Psychiatry 62:30-3. 2001
    ..Factors leading patients to discontinuation of therapy are not well understood. This study investigates when and why patients stop treatment and whether they inform their doctors...
  60. ncbi Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions
    Nicola Casacalenda
    Institute of Community and Family Psychiatry, Department of Psychiatry, Jewish General Hospital and McGill University, Montreal, Quebec, Canada
    Am J Psychiatry 159:1354-60. 2002
    ..The aim of this study was to assess the percentages of full remission in studies of patients with major depressive disorder in which pharmacotherapy, psychotherapy, and control conditions were directly compared...
  61. ncbi Genetic predictors of response to antidepressants in the GENDEP project
    Rudolf Uher
    MRC Social Genetic and Developmental Psychiatry Center, Institute of Psychiatry, King s College London, London, UK
    Pharmacogenomics J 9:225-33. 2009
    ..The single marker associations explained only a small proportion of variance in response to antidepressants, indicating a need for a multivariate approach to prediction...
  62. ncbi Preclinical models: status of basic research in depression
    Eric J Nestler
    Department of Psychiatry and Center for Basic Neuroscience, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Biol Psychiatry 52:503-28. 2002
    ....
  63. pmc Serotonin and depression: a disconnect between the advertisements and the scientific literature
    Jeffrey R Lacasse
    Florida State University College of Social Work, Tallahassee, Florida, United States of America
    PLoS Med 2:e392. 2005
  64. ncbi A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders
    Marcelo Feijo de Mello
    Department of Psychiatry, Federal University of Sao Paulo, São Paulo SP 04026 010, Brazil
    Eur Arch Psychiatry Clin Neurosci 255:75-82. 2005
    ..The aim of this study is to summarize findings from controlled trials of the efficacy of IPT in the treatment of depressive spectrum disorders (DSD) using a meta-analytic approach...
  65. ncbi Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker?
    Marcus Ising
    Max Planck Institute of Psychiatry, Munich, Germany
    Biol Psychiatry 62:47-54. 2007
    ..In the present study, we examined whether change in HPA system function during the first weeks of hospitalization predicts response to antidepressant treatment in major depression and thus constitutes a potential biomarker...
  66. ncbi A new approach to the assessment of the treatment effects of somatoform disorders
    Winfried Rief
    Department of Clinical Psychology and Psychotherapy, Philipps University of Marburg, Germany
    Psychosomatics 44:492-8. 2003
    ..In sum, the SOMS-7 seems to be a comprehensive, reliable, and valid instrument for the evaluation of treatment effects in patients with somatoform disorders...
  67. pmc Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates
    Tarique D Perera
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University Medical Center and New York State Psychiatric Institute, New York, New York, United States of America
    PLoS ONE 6:e17600. 2011
    ..Pen-3 subjects 2 weeks of irradiation (N = 4) or sham-irradiation (N = 2) and then exposed to 15 weeks of stress and fluoxetine. Dependent measures were weekly behavioral observations and postmortem neurogenesis levels...
  68. ncbi Recurrence after recovery from major depressive disorder during 15 years of observational follow-up
    T I Mueller
    NIMH Collaborative Program on the Psychobiology of Depression Clinical Studies, Brown University School of Medicine, Providence, RI 02906, USA
    Am J Psychiatry 156:1000-6. 1999
    ....
  69. pmc The glucocorticoid receptor: pivot of depression and of antidepressant treatment?
    Christoph Anacker
    King s College London, Institute of Psychiatry, Centre for the Cellular Basis of Behaviour CCBB, Department of Psychological Medicine, Section of Perinatal Psychiatry and Stress, Psychiatry and Immunology SPI Lab, 125 Coldharbour Lane, London SE5 9NU, UK
    Psychoneuroendocrinology 36:415-25. 2011
    ..We will review some of the evidence for modulation of the GR by antidepressants and we will provide further insight into how antidepressants may regulate the GR to overcome depressive symptoms...
  70. ncbi Mindfulness-based cognitive therapy to prevent relapse in recurrent depression
    Willem Kuyken
    Mood Disorders Centre, University of Exeter, Exeter, Devon, UK
    J Consult Clin Psychol 76:966-78. 2008
    ..Rates of ADM usage in the MBCT group was significantly reduced, and 46 patients (75%) completely discontinued their ADM. For patients treated with ADM, MBCT may provide an alternative approach for relapse prevention...
  71. ncbi Adult hippocampal neurogenesis in depression
    Amar Sahay
    Department of Neuroscience, Division of Integrative Neuroscience, Columbia University, 1051 Riverside Drive, Box 87, PI Annex, Room 767B, New York, New York 10032, USA
    Nat Neurosci 10:1110-5. 2007
    ..Finally, we speculate on how increased adult hippocampal neurogenesis may modulate dentate gyrus function to confer the behavioral effects of antidepressants...
  72. pmc Exercise and pharmacotherapy in the treatment of major depressive disorder
    James A Blumenthal
    Department of Psychiatry and Behavioral Sciences, Box 3119, Duke University Medical Center, Durham, NC, USA
    Psychosom Med 69:587-96. 2007
    ....
  73. ncbi Cost of depression among adults in England in 2000
    Christine M Thomas
    Organon Laboratories Ltd, Cambridge, London, UK
    Br J Psychiatry 183:514-9. 2003
    ..The cost of depression in the UK was estimated at pound 3.5 billion almost a decade ago. The shift to community-based management for depression alongside the availability of more accurate data have allowed these estimates to be revised...
  74. ncbi Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study
    Cheng Ta Li
    Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan
    Neuroimage 50:347-56. 2010
    ..Voxel-based structural deficits in the left DLPFC may characterize a subgroup of people with recurrent MDD who respond poorly to antidepressants...
  75. ncbi Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments
    M Bilici
    Department of Psychiatry, School of Medicine, Karadeniz Technical University, 61080, Trabzon, Turkey
    J Affect Disord 64:43-51. 2001
    ....
  76. ncbi Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline
    Siegfried Kasper
    Department of Psychiatry and Psychotherapy, Medical University Vienna, MUV, AKH, Wahringer Gurtel 18 20, A 1090 Wien, Austria
    J Clin Psychiatry 71:109-20. 2010
    ....
  77. ncbi Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain
    Tomi Rantamäki
    Neuroscience Center, University of Helsinki, PO Box 56, 00014 Helsinki, Finland
    Neuropsychopharmacology 32:2152-62. 2007
    ..In conclusion, our data suggest that rapid activation of the TrkB neurotrophin receptor and PLCgamma1 signaling is a common mechanism for all antidepressant drugs...
  78. ncbi The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression
    Heinz Grunze
    Newcastle University, RVI, Division of Psychiatry, Institute of Neuroscience, Newcastle upon Tyne, UK
    World J Biol Psychiatry 11:81-109. 2010
    ..Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute bipolar depression in adults...
  79. pmc Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants
    Kelly Posner
    Division of Child and Adolescent Psychiatry, Columbia University New York State Psychiatric Institute, New York, NY 10032, USA
    Am J Psychiatry 164:1035-43. 2007
    ....
  80. ncbi Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action
    Catherine J Harmer
    University Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK
    Br J Psychiatry 195:102-8. 2009
    ..The neuropharmacological actions of antidepressants are well characterised but our understanding of how these changes translate into improved mood are still emerging...
  81. ncbi Convergent animal and human evidence suggests a role of PPM1A gene in response to antidepressants
    Karim Malki
    Institute of Psychiatry, King s College London, United Kingdom
    Biol Psychiatry 69:360-5. 2011
    ..We report on an integrative analysis from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study using gene expression from mice to inform prioritization in a human pharmacogenetic study...
  82. pmc Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression
    Maha Elsayed
    Division of Molecular Psychiatry, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, Yale University School of Medicine, New Haven, CT 06508, USA
    Biol Psychiatry 72:258-65. 2012
    ....
  83. pmc Suffering in silence: reasons for not disclosing depression in primary care
    Robert A Bell
    Departments of Communication and Public Health Sciences, University of California, Davis, Davis, California 95616, USA
    Ann Fam Med 9:439-46. 2011
    ..Depression symptoms are underreported by patients. We thus assessed individuals' reasons for not disclosing depression to their primary care physician...
  84. ncbi The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling
    J M Bessa
    Life and Health Science Research Institute ICVS, School of Health Sciences, University of Minho, Braga, Portugal
    Mol Psychiatry 14:764-73, 739. 2009
    ....
  85. pmc Personalized medicine for depression: can we match patients with treatments?
    Gregory E Simon
    Group Health Research Institute, Seattle, WA 98101, USA
    Am J Psychiatry 167:1445-55. 2010
    ..Response to specific depression treatments varies widely among individuals. Understanding and predicting that variation could have great benefits for people living with depression...
  86. pmc Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response
    M L Wong
    Department of Psychiatry and Behavioral Sciences, Center on Pharmacogenomics, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Mol Psychiatry 13:800-12. 2008
    ..8% of the attributable risk in Mexican Americans with moderate MDD. Immune function genes are highly variable; therefore, different genes might be implicated in distinct population groups...
  87. ncbi Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study
    Jordan W Smoller
    Department of Psychiatry, Massachusetts General Hospital, Boston, 02114, USA
    Arch Intern Med 169:2128-39. 2009
    ..Antidepressants are commonly prescribed medications, but their effect on cardiovascular morbidity and mortality remains unclear...
  88. ncbi Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment
    Arusha Farahani
    Division of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, New York, USA
    J Clin Psychiatry 73:486-96. 2012
    ..To perform a meta-analysis of antidepressant-antipsychotic cotreatment versus antidepressant or antipsychotic monotherapy for psychotic depression...
  89. ncbi A psychoneuroimmunological review on cytokines involved in antidepressant treatment response
    Debbie G A Janssen
    Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Hum Psychopharmacol 25:201-15. 2010
    ..The review focuses on the influence of antidepressants on cytokines, and on how treatment response might be affected by genetic variants of cytokines...
  90. pmc Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder
    Nancy Diazgranados
    National Institute of Mental Health, and Department of Human Health Services, Bethesda, Maryland, USA
    J Clin Psychiatry 71:1605-11. 2010
    ..We examined the effects of a single dose of ketamine on suicidal ideation in subjects with treatment-resistant major depressive disorder (MDD)...
  91. ncbi National patterns in antidepressant medication treatment
    Mark Olfson
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Arch Gen Psychiatry 66:848-56. 2009
    ..Antidepressants have recently become the most commonly prescribed class of medications in the United States...
  92. ncbi Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update
    Edoardo Spina
    Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy
    Clin Ther 30:1206-27. 2008
    ..Rather, concern about drug interactions with second-generation antidepressants is based on their in vitro potential to inhibit > or = 1 CYP isozyme...
  93. ncbi SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants
    Stephen M Stahl
    Department of Psychiatry, University of California, San Diego, San Diego, CA, USA
    CNS Spectr 10:732-47. 2005
    ..Duloxetine and milnacipran appear better tolerated and essentially devoid of cardiovascular toxicity...
  94. ncbi Glutamate-based antidepressants: 20 years on
    Phil Skolnick
    Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA
    Trends Pharmacol Sci 30:563-9. 2009
    ..Here we describe evidence that glutamate-based therapies might represent an effective alternative to biogenic-amine-based agents for depression and provide perspectives on the development of these agents...
  95. ncbi Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study
    Pierre Blier
    University of Ottawa Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada K1Z 7K4
    Am J Psychiatry 167:281-8. 2010
    ..In this double-blind study, the authors sought to produce evidence for the superiority of different combinations of antidepressant drugs from treatment initiation...
  96. ncbi Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action
    Bernadeta Szewczyk
    Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, Pl 31 343 Krakow, Poland
    Pharmacol Rep 60:588-9. 2008
    ..All the available data indicate the importance of zinc and magnesium homeostasis in the psychopathology and therapy of affective disorders...
  97. pmc Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look
    Lucie Opatrny
    Division of Clinical Epidemiology, McGill University Health Center, McGill University, Montreal, Canada
    Br J Clin Pharmacol 66:76-81. 2008
    ....
  98. ncbi Zinc deficiency induces enhanced depression-like behaviour and altered limbic activation reversed by antidepressant treatment in mice
    N Whittle
    Department of Pharmacology and Toxicology, Institute of Pharmacy, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria
    Amino Acids 36:147-58. 2009
    ..Taken together these data support the link between low Zn levels and depression-like behaviour and suggest experimentally-induced Zn deficiency as a putative model of depression in mice...
  99. ncbi Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression
    Judith E Bosmans
    Health Technology Assessment Unit, Institute for Research in Extramural Medicine, VU University Medical Center, Amsterdam, The Netherlands
    J Affect Disord 111:106-12. 2008
    ..The objective of this study was to evaluate whether usual care without antidepressants is equivalent to (i.e. as effective as and as expensive as) usual care with antidepressants in patients with minor or mild-major depression...
  100. ncbi How can we realize the promise of personalized antidepressant medicines?
    Florian Holsboer
    Max Planck Institute of Psychiatry, Kraepelinstrasse 2 10, 80804 Munich, Germany
    Nat Rev Neurosci 9:638-46. 2008
    ..This process will require many further steps and collaboration between basic and clinical neuroscience...

Research Grants66

  1. Remodeling Neuronal Chromatin in Mouse Models for Depression
    Schahram Akbarian; Fiscal Year: 2013
    ..Then, indirectly, the chromatin changes brought about by Setdb1 result in certain adaptations in the communication between nerve cells, ultimately resulting in an antidepressant-like effect. ..
  2. Molecular mechanisms of bacterial homologs of neurotransmitter:sodium symporters
    Jonathan A Javitch; Fiscal Year: 2013
    ..abstract_text> ..
  3. RNA editing in a transgenic mouse model of behavioral despair and anxiety.
    Minati Singh; Fiscal Year: 2010
    ..Predicting clinical outcomes from a rodent model of psychological depression may further prove to be useful for understanding the efficacy and tolerability of antidepressants. ..
  4. Predictors of Treatment Response Relapse and Recurrence in Major Depression
    W Edward Craighead; Fiscal Year: 2012
    ....
  5. NORADRENERGIC SYSTEM IN DEPRESSION
    GREGORY ALLEN ORDWAY; Fiscal Year: 2012
    ..Understanding the molecular pathology of this disorder holds the promise of identifying new biological targets for the development of improved treatments. ..
  6. Biogenic Amine Transporters: Mechanisms of Ligand Interaction
    MAARTEN E REITH; Fiscal Year: 2013
    ..abstract_text> ..
  7. HORMONE-NEUROTRANSMITTER INTERACTIONS IN THE BRAIN
    Elaine M Hull; Fiscal Year: 2011
    ....
  8. Epigenetic modulation of antidepressant efficacy
    Claudia Schmauss; Fiscal Year: 2013
    ..Positive results from these studies could identify a new biomarker capable of predicting antidepressant treatment response. ..
  9. Use of a mouse model of anxious depression to assess the safety of pediatric anti
    Bernhard Luscher; Fiscal Year: 2010
    ..In addition, they may advance the design and safety of antidepressant and anxiolytic therapies directed specifically at pediatric and adolescent patients. ..
  10. The Role of Prefrontal Cortex in Emotion Regulation
    MICHAEL R KOENIGS; Fiscal Year: 2012
    ..The proposed research will provide new information about how the brain functions to regulate negative emotion. ..
  11. GABAA subtype-specific pharmacological modulation of reward-related behavior
    Uwe Rudolph; Fiscal Year: 2010
    ....
  12. INHERITED VARIATIONS IN DRUG METABOLIZING ENZYMES
    Richard M Weinshilboum; Fiscal Year: 2013
    ....
  13. PSYCHOSTIMULANT RECOGNITION BY SEROTONIN TRANSPORTERS
    Eric L Barker; Fiscal Year: 2010
    ..e., the serotonin transporter) and offer new strategies to combat the addictive properties of these substances. ..
  14. CRCNS: Computational Model for Neural Stem Cell Divisions in the Adult Brain
    Alexei Koulakov; Fiscal Year: 2013
    ..Because the lifetime incidence of depression in the US is more than 12% in men and 20% in women, our studies may substantially contribute to public health. ..
  15. The Effects of 5-HT Deficiency on Responses to Stress and Antidepressant Drugs
    Benjamin D Sachs; Fiscal Year: 2013
    ..e. neurogenic) consequences of hyposerotonergia in mice and will enhance our understanding of the mechanisms underlying depressive-like behaviors and antidepressant-like responses. ..
  16. Serotonin Reuptake Inhibitors and 5-HT1A Receptors
    George Battaglia; Fiscal Year: 2009
    ..abstract_text> ..
  17. Development of rat models of the effort-related symptoms of depression
    John D Salamone; Fiscal Year: 2013
    ..The proposed experiments are designed to test the feasibility of using these procedures as potential models of the effort-related symptoms of depression and other disorders. ..
  18. Neurobiological Mechanisms of Antidepressant Effects
    David A Morilak; Fiscal Year: 2013
    ..The results will therefore generate new knowledge upon which to develop strategies that are more customized, rapid, specific and effective in the treatment of depression. ..
  19. Factors Regulating NE Transporter Localization in PFC
    Susan R Sesack; Fiscal Year: 2011
    ..The findings from these studies will provide valuable information regarding the normal functions of the central NE system and its role in the pathophysiology and treatment of mental disorders. ..
  20. Regulation of response to chronic antidepressant treatment by MeCP2
    ANNE ELIZABETH WEST; Fiscal Year: 2013
    ....
  21. REGULATION OF HIPPOCAMPAL NEUROGENESIS BY ANTIDEPRESSANTS
    Irwin Lucki; Fiscal Year: 2013
    ....
  22. Phagocytosis of dying cells, adult neurogenesis and depression
    Kodi S Ravichandran; Fiscal Year: 2013
    ..Our studies might also point to potentially new therapeutic approaches for depression, i.e. enhancing the phagocytic function of neurogenic niche phagocytes. ..
  23. REGULATION OF HIPPOCAMPAL NEUROGENESIS BY ANTIDEPRESSANTS
    Irwin Lucki; Fiscal Year: 2009
    ..mouse strain;2) show whether environmental stress plays a similar role in causing antidepressant drugs to alter neurogenesis and behavior;and 3) determine whether hippocampal BDNF serves as a mechanism underlying ..
  24. PDE4B Inhibitors For Treating Major Depression
    Mark E Gurney; Fiscal Year: 2013
    ....
  25. Monoamine Transporter Regulation and Antidepressant Activity
    JAMES O DONNELL; Fiscal Year: 2009
    ..abstract_text> ..
  26. Predictors of Antidepressant Treatment Response: The Emory CIDAR
    Helen S Mayberg; Fiscal Year: 2010
    ..Delineation of patient characteristics that predict treatment response to a specific treatment modality will dramatically improve patient outcomes and reduce the risk of inadequate treatment. ..
  27. Novel Triple Uptake Inhibitors for Treatment of Depression
    Aloke K Dutta; Fiscal Year: 2013
    ..Two most potent antidepressant molecules will be tested for their antianxiety effect and also on expression of brain derived neurotrophic factor (BDNF), implicated in the clinical action of antidepressant drugs. ..
  28. Role of Neurogenesis in Depression and Antidepressant Efficacy
    Jennifer Onksen; Fiscal Year: 2010
    ..Validating neurogenesis as a drug discovery target creates the potential for novel therapeutics in the treatment of depression. ..
  29. Treating Depressed, Cognitively Impaired Elders
    Dimitris N Kiosses; Fiscal Year: 2010
    ....
  30. How Does Exercise Counteract Stress-Induced Tumor Growth
    Rosemarie Schmandt; Fiscal Year: 2010
    ..An understanding of the mechanisms responsible for the beneficial effects of exercise may lead to the development more effective treatment strategies, which will improve the quality of life for all cancer patients. ..
  31. Depression: Synaptic mediation in sleep deprivation
    Pingfu Feng; Fiscal Year: 2013
    ....
  32. Post-Synaptic Mechanisms for Depression and Antidepressants: Studies in Model Sy
    Mark M Rasenick; Fiscal Year: 2010
    ..Understanding these should reveal both biological markers for depression and new classes of compounds to treat this disorder. ..
  33. Organic Cation Transporters as Targets for Novel Antidepressant Drugs
    Wouter Koek; Fiscal Year: 2013
    ....
  34. The Ninth Annual Pharmacogenetics in Psychiatry Meeting
    Anil K Malhotra; Fiscal Year: 2013
    ..abstract_text> ..
  35. Monoamine Transporter Structure-Function Studies
    CHRISTOPHER SURRATT; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  36. Phosphodiesterase-2 and Mood Disorders: Target Validation and Drug Discovery
    Chang Guo Zhan; Fiscal Year: 2010
    ..The proposed research will discover, synthesize, and characterize the neurochemical and behavioral effects of novel PDE2 inhibitors. This may result in the identification of a new class of drugs for treating mood disorders. ..
  37. Validation of beta2 containing nicotinic acetylcholinergic receptors as a potenti
    JONAS O apos GARA HANNESTAD; Fiscal Year: 2010
    ..If this proves successful then it would be possible to develop newer antidepressant drugs to better treat patients with bipolar depression. [unreadable] ..
  38. 5-HT1A RECEPTOR/G PROTEIN COUPLING AND ADAPTATION
    Emanuel Meller; Fiscal Year: 2003
    ..abstract_text> ..
  39. Central betal adrenergic receptors and behavior
    Han Ting Zhang; Fiscal Year: 2004
    ..This will lead to the better understanding of pathophysiology and pharmacotherapy of depression. ..
  40. DEPRESSION--LOCUS COERULEUS AFFECTS DOPAMINE VIA GALANIN
    JAY WEISS; Fiscal Year: 2001
    ..e., by measuring GAL mRNA and GAL concentration in LC cell bodies) and GAL levels in VTA. ..
  41. Lipid raft localization of Gs: a biomarker for depression and therapeutic respons
    Mark M Rasenick; Fiscal Year: 2013
    ....
  42. Galanin and GalR2 Receptors in Antidepressant Treatments
    Tamas Bartfai; Fiscal Year: 2009
    ..The planned work will deepen our knowledge of the galanin/5-HT system in the DRN and its contribution to the effects of antidepressant treatments. ..
  43. Galanin and GaIR2 receptors in antidepressant treatments
    Tamas Bartfai; Fiscal Year: 2005
    ..The planned work will deepen our knowledge of the galanin/5-HT system in the DRN and its contribution to the effects of anti-depressant treatments. ..
  44. G PROTEIN COUPLING IN ANTIDEPRESSANT DRUG ACTION
    Mark Rasenick; Fiscal Year: 2001
    ..Such knowledge should assist in the design of more efficient antidepressant drug therapy and may lead to a true understanding of the molecular basis of mood. ..
  45. METABOLIC ASPECTS OF BODY WEIGHT CHANGE IN DEPRESSION
    Madelyn Fernstrom; Fiscal Year: 1991
    ..The findings may therefore be useful in formulating a pharmacologic strategy that will avoid weight gain as a side- effect to antidepressant treatment...
  46. PHARMACOGENETICS AND RESPONSE TO THERAPY IN OLDER ADULTS
    SUSAN HECKBERT; Fiscal Year: 2000
    ..This project will incorporate advances in molecular biology in the study of response to drug therapy for common conditions, with the goal of improving clinical care of the elderly. ..
  47. The Treatment of Binge Eating Disorder
    Scott Crow; Fiscal Year: 2004
    ..The result of this study could inform the design of trials to treat both binge-eating and promote weight loss. ..
  48. The Treatment of Binge Eating Disorder
    James Mitchell; Fiscal Year: 2004
    ..The result of this study could inform the design of trials to treat both binge-eating and promote weight loss. ..
  49. PSYCHOTROPIC DRUGS, ELECTROSHOCK & BRAIN AMINE UPTAKE
    EDITH HENDLEY; Fiscal Year: 1980
    ..More importantly, our studies should also shed light on the uptake mechanism itself, which is a common mode olfaction of a number of drugs that are popularly abused, e.g. cocaine and amphetamines. ..
  50. Pharmacogenetics of Antidepressant Drugs
    Ma Li Wong; Fiscal Year: 2007
    ..This K-24 award will make possible for the P.I. to significantly increase her time allocation for patient-oriented research and for mentoring of junior trainees and fellows in clinical research. [unreadable] [unreadable]..
  51. Antidepressants and Fibroblast Growth Factor
    Italo Mocchetti; Fiscal Year: 2006
    ..Data from this proposal may help elucidate the therapeutic efficacy of antidepressants in affective disorders. [unreadable] [unreadable]..
  52. Structural Domains Essential for Serotonin Receptor Pharmacology
    Bryan Roth; Fiscal Year: 2006
    ..Novel techniques of protein biochemistry (hydroxyl-mediated 1H/2H exchange), cell biology (yeast 2-hybrid screening) and spectroscopy (FRET/BRET) will be used to arrive at testable models for 5-HT2A-Gq interactions. ..
  53. PSYCHOACTIVE DRUGS: BIOCHEMICAL MECHANISMS OF ACTION
    Elaine Sanders Bush; Fiscal Year: 1990
    ....
  54. HUMAN 5HT RECEPTOR REGULATION BY ANTIDEPRESSANTS
    Stephen Stahl; Fiscal Year: 1992
    ....
  55. ELECTROCONVULSIVE SHOCK EFFECTS ON BRAIN RECEPTORS
    Kenneth Kellar; Fiscal Year: 1990
    ..This information should contribute to an eventual understanding of the neurochemical effects of ECS and antidepressant drugs and potentially to the rationale for the clinical effects of electroconvulsive therapy...
  56. RATIONAL PHARMACOTHERAPY OF PRIMARY INSOMNIA
    Daniel Buysse; Fiscal Year: 2004
    ..The Principal Investigator will mentor trainees in analyses of existing data, design and implementation of the clinical trial, described above, and new studies designed by the trainees themselves. ..
  57. Structural basis for reciprocal regulation of the GTPases tubulin and Gsalpha
    Mark Rasenick; Fiscal Year: 2006
    ....
  58. Alpha-2 Adrenoceptors in Antidepressant Drug Mechanisms
    H Happe; Fiscal Year: 2009
    ..This research should inform future studies in the regulation and alteration of neurotransmitter interactions important in depressive disorders and the mechanisms of therapeutic action for antidepressant drugs. ..
  59. ANTIDEPRESSANT THERAPY FOR METHADONE-TREATED ADDICTS
    George Woody; Fiscal Year: 1980
    ..Plasma samples are also taken at specified intervals and an attempt will be made to correlate blood levels of the antidepressants with clinical response...
  60. ONTOGENY OF DEPRESSIVE SUBSTRATES
    Pingfu Feng; Fiscal Year: 2001
    ..In doing so, the proposed work may help in the search for early prevention of ED, and in more precisely targeted treatments of ED. ..
  61. ANTIPSYCHOTIC DRUG EFFECTS--TSTS OF NE VS DA MECHANISM
    Bruce Cohen; Fiscal Year: 1990
    ..In addition, such knowledge may provide clues regarding the pathophysiology of the idiopathic psychoses...
  62. REGULATION OF 5HT 1B RECEPTORS IN SEROTONERGIC NEURONS
    John Neumaier; Fiscal Year: 2001
    ....
  63. REGULATION OF 5HT1A RECEPTOR FUNCTION
    William Clarke; Fiscal Year: 2003
    ..The integration of brain slice preparations and clonal cell systems Will pernift rigorous study of the regulation of 5-HTI A receptor function. ..
  64. PSYCHOSTIMULANT RECOGNITION BY SEROTONIN TRANSPORTERS
    ERIC BARKER; Fiscal Year: 2003
    ..abstract_text> ..
  65. ANTIDEPRESSANTS: SIGNAL TRANSDUCTION AND GENE EXPRESSION
    Ronald Duman; Fiscal Year: 1993
    ..These studies could elucidate the adaptive-molecular mechanisms which mediate antidepressant therapy as well as the role of pituitary-adrenal hormones in the etiology of depression...
  66. BRAIN MESSENGERS AND RECEPTORS
    Christopher Ross; Fiscal Year: 1991
    ..These studies should clarify the neuroanatomy and molecular biology of brain opioid systems and their role in the pathophysiology of neuropsychiatric illness...